Clinical trial
Effect of BIBW 2948 BS in COPD
NCT00423137 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00423137 |
|---|---|
| Title | Effect of BIBW 2948 BS in COPD |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of a 4-week Treatment of 15 and 30 mg b.i.d BIBW2948 BS (Inhalation Powder, Hard Capsule for HandiHaler®) on Epithelial Mucin Stores and the Safety and Efficacy in COPD Patients With Symptoms Associated With… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic |
| Intervention type | Drug |
| Interventions | BIBW 2948 BS, Placebo |
| Enrollment | 48 |
| Start date | Jan 17, 2007 |
| Primary completion | Jul 9, 2008 |
| Completion | Jul 9, 2008 |
| First posted | Jan 18, 2007 |
| Last update posted | Nov 19, 2021 |
| Countries | Germany, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: